300636 同和药业
已收盘 05-15 15:00:00
资讯
新帖
简况
同和药业(300636)披露向特定对象发行股票持续督导保荐总结报告书,5月15日股价下跌1.6%
证券之星 · 05-15 18:18
同和药业(300636)披露向特定对象发行股票持续督导保荐总结报告书,5月15日股价下跌1.6%
同和药业宣布美国FDA对其医药产品发出DMF首封充分信函
美股速递 · 05-14 12:02
同和药业宣布美国FDA对其医药产品发出DMF首封充分信函
同和药业(300636.SZ):原料药卡格列净获得美国FDA注册批准函
智通财经 · 05-14 11:49
同和药业(300636.SZ):原料药卡格列净获得美国FDA注册批准函
同和药业(300636)披露将举行2025年度网上业绩说明会,5月08日股价上涨1.95%
证券之星 · 05-08
同和药业(300636)披露将举行2025年度网上业绩说明会,5月08日股价上涨1.95%
【机构调研记录】中加基金调研同和药业、章源钨业等3只个股(附名单)
证券之星 · 05-01
【机构调研记录】中加基金调研同和药业、章源钨业等3只个股(附名单)
同和药业(300636)3月31日股东户数1.6万户,较上期增加6.16%
证券之星 · 04-29
同和药业(300636)3月31日股东户数1.6万户,较上期增加6.16%
图解同和药业年报:第四季度单季净利润同比下降197.47%
证券之星 · 04-29
图解同和药业年报:第四季度单季净利润同比下降197.47%
同和药业:公司重视全体股东尤其是中小投资者的合法权益
证券之星 · 04-28
同和药业:公司重视全体股东尤其是中小投资者的合法权益
3月27日同和药业涨5.04%,湘财医药健康混合A基金重仓该股
证券之星 · 03-27
3月27日同和药业涨5.04%,湘财医药健康混合A基金重仓该股
同和药业最新公告:公司原料药“富马酸伏诺拉生”通过CDE审批
证券之星 · 02-25
同和药业最新公告:公司原料药“富马酸伏诺拉生”通过CDE审批
同和药业:CMO/CDMO业务有望在2027、2028年实现快速增长
证券之星 · 02-12
同和药业:CMO/CDMO业务有望在2027、2028年实现快速增长
同和药业(300636.SZ):甲苯磺酸艾多沙班原料药通过CDE审批
智通财经 · 02-04
同和药业(300636.SZ):甲苯磺酸艾多沙班原料药通过CDE审批
股市必读:同和药业(300636)1月28日董秘有最新回复
证券之星 · 01-29
股市必读:同和药业(300636)1月28日董秘有最新回复
同和药业:2026年公司二厂区二期试生产的两个车间正式投产后,年产能可达15-16亿元
证券之星 · 01-28
同和药业:2026年公司二厂区二期试生产的两个车间正式投产后,年产能可达15-16亿元
同和药业(300636)披露2025年度持续督导定期现场检查报告,1月5日股价上涨2.0%
证券之星 · 01-05
同和药业(300636)披露2025年度持续督导定期现场检查报告,1月5日股价上涨2.0%
同和药业:公司仅在定期报告中披露截至报告期末的股东人数
证券日报 · 2025-12-05
同和药业:公司仅在定期报告中披露截至报告期末的股东人数
同和药业:新产能扩建已有潜在客户
证券之星 · 2025-12-02
同和药业:新产能扩建已有潜在客户
同和药业最新公告:公司原料药恩格列净通过药品GMP符合性检查
证券之星 · 2025-03-11
同和药业最新公告:公司原料药恩格列净通过药品GMP符合性检查
同和药业(300636.SZ)通过药品GMP符合性检查
智通财经 · 2025-03-11
同和药业(300636.SZ)通过药品GMP符合性检查
加载更多
公司概况
公司名称:
江西同和药业股份有限公司
所属行业:
医药制造业
上市日期:
2017-03-31
主营业务:
江西同和药业股份有限公司的主营业务是化学原料药和医药中间体的研发、生产和销售。公司的主要产品是加巴喷丁原料药、瑞巴派特原料药、醋氯芬酸原料药、塞来昔布原料药、坎地沙坦酯原料药、阿齐沙坦原料药、沙坦类中间体、达比加群酯原料药、替格瑞洛原料药、阿哌沙班原料药、利伐沙班原料药、维格列汀原料药、恩格列净原料药、盐酸文拉法辛原料药、阿戈美拉汀原料药、非布司他原料药、米拉贝隆原料药。
发行价格:
14.47
{"stockData":{"symbol":"300636","market":"SZ","secType":"STK","nameCN":"同和药业","latestPrice":7.37,"timestamp":1778828601000,"preClose":7.49,"halted":0,"volume":5666050,"delay":0,"changeRate":-0.016,"floatShares":367000000,"shares":420000000,"eps":0.1693,"marketStatus":"已收盘","change":-0.12,"latestTime":"05-15 15:00:00","open":7.48,"high":7.52,"low":7.34,"amount":42031600,"amplitude":0.024,"askPrice":7.38,"askSize":11,"bidPrice":7.37,"bidSize":21,"shortable":0,"etf":0,"ttmEps":0.1693,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":7.49,"symbolType":"stock","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":8.24,"lowLimit":6.74,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":419951495,"isCdr":false,"pbRate":1.32,"roa":"--","peRate":43.532191,"roe":"0.79%","epsLYR":0.174,"committee":0.302326,"marketValue":3095000000,"turnoverRate":0.0154,"status":1,"floatMarketCap":2707000000},"requestUrl":"/m/hq/s/300636/","defaultTab":"news","newsList":[{"id":"2635083942","title":"同和药业(300636)披露向特定对象发行股票持续督导保荐总结报告书,5月15日股价下跌1.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635083942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635083942?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:18","pubTimestamp":1778840301,"startTime":"0","endTime":"0","summary":"近日,同和药业披露《招商证券股份有限公司关于江西同和药业股份有限公司向特定对象发行股票持续督导保荐总结报告书》。公告显示,招商证券作为该公司向特定对象发行股票的保荐机构,持续督导期已于2025年12月31日届满。持续督导期间,保荐机构按规定开展尽职调查、文件申报、信息披露审阅、募集资金使用监督等工作,未发现重大违规事项。公司募集资金尚未使用完毕,保荐机构将在督导期结束后继续对募集资金存放与使用进行专项督导。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500035378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169739277","title":"同和药业宣布美国FDA对其医药产品发出DMF首封充分信函","url":"https://stock-news.laohu8.com/highlight/detail?id=1169739277","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169739277?lang=zh_cn&edition=full","pubTime":"2026-05-14 12:02","pubTimestamp":1778731336,"startTime":"0","endTime":"0","summary":"同和药业宣布,美国食品药品监督管理局已对其旗下的一款医药产品发出药物主文件首封充分信函。这一进展标志着该产品在监管审查流程中迈出了关键一步,为公司后续的市场拓展计划奠定了重要的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635769079","title":"同和药业(300636.SZ):原料药卡格列净获得美国FDA注册批准函","url":"https://stock-news.laohu8.com/highlight/detail?id=2635769079","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635769079?lang=zh_cn&edition=full","pubTime":"2026-05-14 11:49","pubTimestamp":1778730580,"startTime":"0","endTime":"0","summary":"智通财经APP讯,同和药业 发布公告,公司于近日收到美国食品药品监督管理局签发的卡格列净原料药注册批准函DMF First Adequate Letter。卡格列净产品获得美国FDA签发的 FA Letter,表明 FDA 已完成对公司卡格列净原料药 DMF 文件的技术审评,可满足关联制剂客户的 ANDA 申报要求。卡格列净原料药此次通过技术审评,有利于公司拓展市场、开拓客户,将对公司进一步扩大国际市场业务起到积极作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","300636","BK4588","LABU","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633431273","title":"同和药业(300636)披露将举行2025年度网上业绩说明会,5月08日股价上涨1.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633431273","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633431273?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:51","pubTimestamp":1778233909,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,同和药业报收于7.84元,较前一交易日上涨1.95%,最新总市值为32.92亿元。同和药业近日发布《关于举行2025年度网上业绩说明会的公告》。公告显示,公司已于2026年4月29日在巨潮资讯网披露《2025年年度报告》,并将于2026年5月13日下午15:00-16:00通过深圳证券交易所“互动易”平台举行2025年度网上业绩说明会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800032200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632693558","title":"【机构调研记录】中加基金调研同和药业、章源钨业等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632693558","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632693558?lang=zh_cn&edition=full","pubTime":"2026-05-01 08:01","pubTimestamp":1777593703,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及4月30日披露的机构调研信息,中加基金近期对3家上市公司进行了调研,相关名单如下:1)同和药业 调研纪要:2025年新产品收入同比增长近15%,销售收入占比达50.05%,首次超过老产品;2026年一季度同比增长23.64%,占比达54.07%。2)章源钨业 调研纪要:2025年,公司营业收入520,194.40万元,较上年同期增长41.62%;归属于上市公司股东的净利润29,042.56万元,较上年同期增长68.82%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100008104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002378","BK0233","BK0182","300636","BK0077","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631591561","title":"同和药业(300636)3月31日股东户数1.6万户,较上期增加6.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631591561","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631591561?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:04","pubTimestamp":1777457051,"startTime":"0","endTime":"0","summary":"证券之星消息,近日同和药业披露,截至2026年3月31日公司股东户数为1.6万户,较12月31日增加930.0户,增幅为6.16%。在化学制药行业个股中,同和药业股东户数低于行业平均水平,截至3月31日,化学制药行业平均股东户数为3.6万户。从股价来看,2025年12月31日至2026年3月31日,同和药业区间涨幅为8.52%,在此期间股东户数增加930.0户,增幅为6.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900056975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631580434","title":"图解同和药业年报:第四季度单季净利润同比下降197.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631580434","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631580434?lang=zh_cn&edition=full","pubTime":"2026-04-29 03:08","pubTimestamp":1777403282,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业2025年年报显示,当年度公司主营收入8.29亿元,同比上升9.19%;归母净利润7309.14万元,同比下降31.42%;扣非净利润6274.47万元,同比下降37.02%;其中2025年第四季度,公司单季度主营收入1.92亿元,同比上升1.83%;单季度归母净利润-1057.32万元,同比下降197.47%;单季度扣非净利润-1354.33万元,同比下降306.49%;负债率28.78%,投资收益-111.67万元,财务费用-1360.07万元,毛利率30.26%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900007808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630997323","title":"同和药业:公司重视全体股东尤其是中小投资者的合法权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2630997323","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630997323?lang=zh_cn&edition=full","pubTime":"2026-04-28 11:33","pubTimestamp":1777347233,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业04月27日在投资者关系平台上答复投资者关心的问题。请问公司是否在为保护中小投资者做过切实举动?公司重视全体股东尤其是中小投资者的合法权益,始终严格遵照《公司法》《上市公司信息披露管理办法》及《公司章程》的规定,依法保障投资者知情权。股东查阅获悉的股东名册信息应当仅供该股东自身的正当目的使用,不得告知或泄露给其他方。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800036922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622184939","title":"3月27日同和药业涨5.04%,湘财医药健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622184939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622184939?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:17","pubTimestamp":1774599446,"startTime":"0","endTime":"0","summary":"证券之星消息,3月27日同和药业涨5.04%,收盘报7.92元,换手率2.47%,成交量9.09万手,成交额7091.6万元。重仓同和药业的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为湘财基金的湘财医药健康混合A。湘财医药健康混合A目前规模为0.16亿元,最新净值1.6505,较上一交易日上涨0.0%,近一年上涨37.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614470000","title":"同和药业最新公告:公司原料药“富马酸伏诺拉生”通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2614470000","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614470000?lang=zh_cn&edition=full","pubTime":"2026-02-25 18:10","pubTimestamp":1772014252,"startTime":"0","endTime":"0","summary":"同和药业(300636.SZ)公告称,公司提交的“富马酸伏诺拉生”原料药通过了国家药品监督管理局药品审评中心(CDE)审批,已批准在国内上市制剂中使用。该原料药主要用于治疗反流性食管炎,通过CDE审批有利于公司拓展产品在国内市场的销售,形成国内外市场同步销售的良好格局。但具体销售情况存在一定不确定性,公司将履行信息披露义务。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500031452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610926478","title":"同和药业:CMO/CDMO业务有望在2027、2028年实现快速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2610926478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610926478?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:53","pubTimestamp":1770900790,"startTime":"0","endTime":"0","summary":"公司明确表示承接跨国药企的CMO业务,并服务于原研公司。近年公司在CMO/CDMO项目上新增项目有所增多,在部分老项目逐渐退出市场的情况下,公司将积极服务现有项目,大力开拓新项目,争取新项目能早日放量以弥补现有老项目订单减少带来的缺口。CMO/CDMO业务有望在2027、2028年实现快速增长。公司将密切关注AI技术的发展,根据行业特点及公司的实际情况,积极推动AI技术在研发和生产的应用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200037738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608352963","title":"同和药业(300636.SZ):甲苯磺酸艾多沙班原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2608352963","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608352963?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:48","pubTimestamp":1770198539,"startTime":"0","endTime":"0","summary":"智通财经APP讯,同和药业(300636.SZ)公告,公司提交的“甲苯磺酸艾多沙班”原料药通过了CDE审批。甲苯磺酸艾多沙班是一种口服抗凝药物,主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞,以及治疗或预防深静脉血栓和肺栓塞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082519.USD","BK4017","LU1223083913.SGD","CDE","LU1223082196.USD","300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607741725","title":"股市必读:同和药业(300636)1月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2607741725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607741725?lang=zh_cn&edition=full","pubTime":"2026-01-29 02:38","pubTimestamp":1769625494,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘,同和药业报收于8.2元,下跌3.53%,换手率3.1%,成交量11.4万手,成交额9485.96万元。董秘最新回复投资者: 董秘您好,想向您咨询以下几个问题: 1.公司当前最新的销售毛利率与净利率分别是多少?当日关注点来自交易信息汇总:1月28日主力资金净流出412.64万元,散户资金净流入346.09万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900001493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606793559","title":"同和药业:2026年公司二厂区二期试生产的两个车间正式投产后,年产能可达15-16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606793559","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606793559?lang=zh_cn&edition=full","pubTime":"2026-01-28 15:42","pubTimestamp":1769586126,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业01月28日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,想向您咨询以下几个问题: 1.公司当前最新的销售毛利率与净利率分别是多少?","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800021697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601594838","title":"同和药业(300636)披露2025年度持续督导定期现场检查报告,1月5日股价上涨2.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601594838","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601594838?lang=zh_cn&edition=full","pubTime":"2026-01-05 23:17","pubTimestamp":1767626233,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘,同和药业报收于7.66元,较前一交易日上涨2.0%,最新总市值为32.17亿元。该股当日开盘7.5元,最高7.68元,最低7.49元,成交额达4524.95万元,换手率为1.62%。近日,招商证券股份有限公司发布了关于江西同和药业股份有限公司2025年度持续督导定期现场检查报告。公司业绩无大幅波动,与同行业比较无明显异常,股东及公司承诺均得到完全履行。现场检查未发现重大问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500041079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589576897","title":"同和药业:公司仅在定期报告中披露截至报告期末的股东人数","url":"https://stock-news.laohu8.com/highlight/detail?id=2589576897","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589576897?lang=zh_cn&edition=full","pubTime":"2025-12-05 20:04","pubTimestamp":1764936240,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月5日,同和药业在互动平台回答投资者提问时表示,为保证所有投资者平等获悉公司信息,公司仅在各定期报告中披露截至报告期末的股东人数情况。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-05/doc-infzuert9398534.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-05/doc-infzuert9398534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588423087","title":"同和药业:新产能扩建已有潜在客户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588423087","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588423087?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:18","pubTimestamp":1764659905,"startTime":"0","endTime":"0","summary":"证券之星消息,同和药业(300636)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问:周总,请问下公司新产能扩建是否是已有潜在客户,或者已取得客户合作的前提下开展的?谢谢同和药业回复:对的。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200017062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518045797","title":"同和药业最新公告:公司原料药恩格列净通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2518045797","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518045797?lang=zh_cn&edition=full","pubTime":"2025-03-11 17:10","pubTimestamp":1741684207,"startTime":"0","endTime":"0","summary":"同和药业(300636.SZ)公告称,公司于近日收到江西省药品监督管理局的药品GMP符合性检查结果告知书,获悉公司本次检查原料药恩格列净符合药品GMP。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100029949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300636"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518792210","title":"同和药业(300636.SZ)通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2518792210","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518792210?lang=zh_cn&edition=full","pubTime":"2025-03-11 17:08","pubTimestamp":1741684087,"startTime":"0","endTime":"0","summary":"智通财经APP讯,同和药业(300636.SZ)公告,公司于近日收到江西省药品监督管理局的“江西省药品监督管理局药品GMP符合性检查结果告知书(赣药品GMP(2025)第A0020号)”,获悉经现场检查和综合评定,公司本次检查原料药恩格列净符合药品GMP。恩格列净适用于治疗2型糖尿病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300636","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778888487576,"stockEarnings":[{"period":"1week","weight":-0.0599},{"period":"1month","weight":-0.1034},{"period":"3month","weight":-0.1278},{"period":"6month","weight":-0.149},{"period":"1year","weight":0.0136},{"period":"ytd","weight":-0.0186}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江西同和药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"16023人(较上一季度增加6.16%)","perCapita":"22926股","listingDate":"2017-03-31","address":"江西省宜春市奉新县江西奉新高新技术产业园区","registeredCapital":"41995万元","survey":" 江西同和药业股份有限公司的主营业务是化学原料药和医药中间体的研发、生产和销售。公司的主要产品是加巴喷丁原料药、瑞巴派特原料药、醋氯芬酸原料药、塞来昔布原料药、坎地沙坦酯原料药、阿齐沙坦原料药、沙坦类中间体、达比加群酯原料药、替格瑞洛原料药、阿哌沙班原料药、利伐沙班原料药、维格列汀原料药、恩格列净原料药、盐酸文拉法辛原料药、阿戈美拉汀原料药、非布司他原料药、米拉贝隆原料药。","listedPrice":14.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同和药业,300636,同和药业股票,同和药业股票老虎,同和药业股票老虎国际,同和药业行情,同和药业股票行情,同和药业股价,同和药业股市,同和药业股票价格,同和药业股票交易,同和药业股票购买,同和药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同和药业(300636)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同和药业(300636)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}